Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Mysler · SciRah

Researcher profile · Semantic Scholar

E. Mysler

Share profile

E. Mysler — researcher profile on SciRah

h-index: 39
Works: 182
Citations: 15K

Most-cited papers

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
J. Smolen, R. Landewé, J. Bijlsma, G. Burmester +43 more
2020Annals of the Rheumatic Diseases2,268 citations Open access
Semantic Scholar
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
J. Smolen, R. Landewé, S. A. Bergstra, A. Kerschbaumer +44 more
2022Annals of the Rheumatic Diseases1,586 citations Open access
Semantic Scholar
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
G. Burmester, S. Cohen, K. Winthrop, P. Nash +10 more
2023RMD Open199 citations Open access
Semantic Scholar
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
D. Jayne, B. Rovin, E. Mysler, R. Furie +7 more
2022Annals of the Rheumatic Diseases184 citations Open access
Semantic Scholar
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
R. Fleischmann, E. Mysler, L. Bessette, C. Peterfy +7 more
2022RMD Open90 citations Open access
Semantic Scholar
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
D. Aletaha, A. Kerschbaumer, K. Kastrati, C. Dejaco +40 more
2022Annals of the Rheumatic Diseases74 citations Open access
Semantic Scholar
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
K. Winthrop, P. Nash, K. Yamaoka, E. Mysler +5 more
2021Annals of the Rheumatic Diseases70 citations Open access
Semantic Scholar
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
R. Fleischmann, V. Jairath, E. Mysler, D. Nicholls +1 more
2020Rheumatology and Therapy65 citations Open access
Semantic Scholar
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
M. Genovese, E. Mysler, T. Tomita, K. Papp +11 more
2020Rheumatology62 citations Open access
Semantic Scholar
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
D. Jayne, B. Rovin, E. Mysler, R. Furie +7 more
2023Lupus Science and Medicine50 citations Open access
Semantic Scholar
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
R. Fleischmann, J. Curtis, C. Charles-Schoeman, E. Mysler +7 more
2023Annals of the Rheumatic Diseases47 citations Open access
Semantic Scholar
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
P. Conaghan, E. Mysler, Yoshiya Tanaka, B. Da Silva-Tillmann +8 more
2021Drug Safety46 citations Open access
Semantic Scholar
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients
G. Citera, E. Mysler, H. Madariaga, M. Cardiel +12 more
2020Journal of clinical rheumatology41 citations Open access
Semantic Scholar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
E. Mysler, V. Azevedo, S. Danese, Daniel F. Alvarez +4 more
2021Drugs35 citations Open access
Semantic Scholar
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
C. Charles-Schoeman, R. Fleischmann, E. Mysler, Maria Greenwald +12 more
2024Arthritis & Rheumatology34 citations Open access
Semantic Scholar
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
R. Fleischmann, Jerzy Świerkot, Sara K. Penn, P. Durez +7 more
2024RMD Open29 citations Open access
Semantic Scholar
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
C. Charles-Schoeman, Ernest H. S. Choy, I. McInnes, E. Mysler +8 more
2023RMD Open28 citations Open access
Semantic Scholar
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
E. Mysler, M. Caubet, Analí Lizárraga
2021Open Access Rheumatology : Research and Reviews27 citations Open access
Semantic Scholar
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.
Nancy Agmon-Levin, S. Ignatenko, A. Gordienko, Josefina Cortés-Hernández +31 more
2025Annals of the Rheumatic Diseases17 citations Open access
Semantic Scholar
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
E. Mysler, G. Burmester, C. Saffore, John Liu +6 more
2024Advances in Therapy16 citations Open access
Semantic Scholar
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)
S. Cohen, J. Pope, B. Haraoui, E. Mysler +8 more
2021RMD Open16 citations Open access
Semantic Scholar
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
D. Jayne, B. Rovin, E. Mysler, R. Furie +7 more
202113 citations Open access
Semantic Scholar
POS0239 RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3b/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS
C. Charles-Schoeman, R. Fleischmann, E. Mysler, M. Greenwald +8 more
2022Annals of the Rheumatic Diseases12 citations Open access
Semantic Scholar
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges
E. Soriano, E. Mysler, Carlos Ríos, R. Xavier +2 more
2024Expert Opinion on Pharmacotherapy11 citations
Semantic Scholar
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
R. Fleischmann, R. Blanco, F. E. Van den Bosch, L. Bessette +6 more
2024Rheumatology and Therapy10 citations Open access
Semantic Scholar
Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities
J. Tumlin, B. Rovin, Hans-Joachim Anders, E. Mysler +7 more
2024Kidney International Reports9 citations Open access
Semantic Scholar
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
E. Mysler, Analí Lizárraga
2021Rheumatology9 citations Open access
Semantic Scholar
THU0218 INCIDENCE AND RISK FACTORS FOR HERPES ZOSTER IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING UPADACITINIB
K. Winthrop, P. Nash, K. Yamaoka, E. Mysler +6 more
2020Annals of the Rheumatic Diseases9 citations
Semantic Scholar
Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
M. Mortezavi, E. Mysler
2023Therapeutic Advances in Chronic Disease8 citations Open access
Semantic Scholar
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
E. Mysler, Yoshiya Tanaka, A. Kavanaugh, D. Aletaha +7 more
2022Rheumatology8 citations Open access
Semantic Scholar
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy
K. Winthrop, J. Klaff, Sara K. Penn, Yan-Xi Liu +7 more
2025RMD Open7 citations Open access
Semantic Scholar
THU0201 LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 72 WEEKS FROM THE SELECT-COMPARE STUDY
R. Fleischmann, I. Song, J. Enejosa, E. Mysler +6 more
2020Annals of the Rheumatic Diseases7 citations
Semantic Scholar
FRI0140 IMPACT OF BASELINE DEMOGRAPHICS AND DISEASE ACTIVITY ON OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB
M. Weinblatt, E. Mysler, A. Ostor, A. Broadwell +8 more
2020Annals of the Rheumatic Diseases7 citations
Semantic Scholar
Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action.
E. Mysler, O. Monticielo, Ibrahim A. Al-Homood, C. Lau +2 more
2024Modern Rheumatology6 citations Open access
Semantic Scholar
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
Peter C. Taylor, Yun-Fei Chen, J. Pope, M. Weinblatt +7 more
2023Rheumatology and Therapy6 citations Open access
Semantic Scholar
Association between Diabetes and Rheumatoid Arthritis: A Systematic Literature Review
J. Okais, F. Fayad, R. Baddoura, O. A. Tabesh +4 more
2022Open Rheumatology Journal6 citations Open access
Semantic Scholar
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
P. Conaghan, S. Cohen, G. Burmester, E. Mysler +10 more
2021Rheumatology and Therapy6 citations Open access
Semantic Scholar
Efficacy, Safety, and Immunogenicity of Biosimilar Etanercept (Enerceptan) Versus Its Original Form in Combination With Methotrexate in Patients With Rheumatoid Arthritis
I. Strusberg, E. Mysler, G. Citera, D. Siri +13 more
2020Journal of clinical rheumatology6 citations
Semantic Scholar
Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis.
Pedro Santos Moreno, Rodrigo N. Garcia Salinas, C. Caballero-Uribe, M. Brance +28 more
2025The Lancet Rheumatology5 citations
Semantic Scholar
Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
G. Burmester, E. Mysler, Peter C. Taylor, Stephen B. Hall +6 more
2025RMD Open5 citations Open access
Semantic Scholar
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
Patrick G Gavin, E. L. Allman, D. Jayne, E. Mysler +15 more
2025RMD Open5 citations Open access
Semantic Scholar
OP0225 EVALUATION OF RESPONSE TO ADJUVANTED RECOMBINANT ZOSTER VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A RANDOMIZED TRIAL SUB-STUDY
K. Winthrop, J. Klaff, Y. Liu, C. Garcia +7 more
2023Annals of the Rheumatic Diseases5 citations Open access
Semantic Scholar
POS0087 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY
R. Fleischmann, E. Mysler, L. Bessette, C. Peterfy +7 more
20215 citations Open access
Semantic Scholar
Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
E. Mysler, M. Cardiel, R. Xavier, Alejandra López +1 more
2020Journal of clinical rheumatology5 citations Open access
Semantic Scholar
OP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
N. Agmon-Levin, S. Ignatenko, A. Gordienko, J. Cortés-Hernández +32 more
2024Scientific Abstracts4 citations
Semantic Scholar
Editorial: Drug Survival: Treatment of Rheumatic Diseases in the Biologic Era
Lorenzo Di Sanzo, R. Scrivo, E. Soriano, G. Citera +3 more
2022Frontiers in Medicine4 citations Open access
Semantic Scholar
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program
C. Peterfy, V. Strand, A. Friedman, S. Hall +8 more
2021Rheumatology4 citations Open access
Semantic Scholar
Evaluating upadacitinib for the treatment of rheumatoid arthritis
E. Mysler, Analí Lizárraga
2020Expert Opinion on Pharmacotherapy4 citations
Semantic Scholar
THU0211 RADIOGRAPHIC OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE: RESULTS AT 2 YEARS FROM THE SELECT-COMPARE AND SELECT-EARLY STUDIES
C. Peterfy, V. Strand, M. Genovese, A. Friedman +9 more
2020Annals of the Rheumatic Diseases4 citations Open access
Semantic Scholar
Similar and mimics: Latin America biosimilar regulations
Analí Lizárraga, E. Mysler
2019International Journal of Rheumatic Diseases4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Fleischmann×9
Invite
R. Fleischmann — researcher profile on SciRah
N. Khan×8
Invite
N. Khan — researcher profile on SciRah
P. Nash×7
Invite
P. Nash — researcher profile on SciRah
Yoshiya Tanaka×7
Invite
Yoshiya Tanaka — researcher profile on SciRah

×6

Invite

T. Shaw — researcher profile on SciRah

Invite

P. Durez — researcher profile on SciRah

Invite

I. Song — researcher profile on SciRah

Invite

M. Cardiel — researcher profile on SciRah

Invite

K. Winthrop — researcher profile on SciRah

Invite

L. Bessette — researcher profile on SciRah

Invite

X. Bu — researcher profile on SciRah

Invite

G. Citera — researcher profile on SciRah